[1] GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020;396(10258):1223 − 49. https://doi.org/10.1016/S0140-6736(20)30752-2.
[2] Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol 2020;76(25):2982 − 3021. https://doi.org/10.1016/j.jacc.2020.11.010.
[3] Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration. Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment. Lancet Diabetes Endocrinol 2014;2(8):634 − 47. https://doi.org/10.1016/S2213-8587(14)70102-0.
[4] Kontis V, Mathers CD, Rehm J, Stevens GA, Shield KD, Bonita R, et al. Contribution of six risk factors to achieving the 25×25 non-communicable disease mortality reduction target: a modelling study. Lancet 2014;384(9941):427 − 37. https://doi.org/10.1016/S0140-6736(14)60616-4.
[5] Kontis V, Mathers CD, Bonita R, Stevens GA, Rehm J, Shield KD, et al. Regional contributions of six preventable risk factors to achieving the 25 × 25 non-communicable disease mortality reduction target: a modelling study. Lancet Glob Health 2015;3(12):e746 − 57. https://doi.org/10.1016/S2214-109X(15)00179-5.
[6] NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet 2021;398(10304):957 − 80. https://doi.org/10.1016/S0140-6736(21)01330-1.
[7] Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation 2016;134(6):441 − 50. https://doi.org/10.1161/CIRCULATIONAHA.115.018912.
[8] Jafar TH, Gandhi M, de Silva HA, Jehan I, Naheed A, Finkelstein EA, et al. A community-based intervention for managing hypertension in rural South Asia. N Engl J Med 2020;382(8):717 − 26. https://doi.org/10.1056/NEJMoa1911965.
[9] Sun YX, Mu JJ, Wang DW, Ouyang NX, Xing LY, Guo XF, et al. A village doctor-led multifaceted intervention for blood pressure control in rural China: an open, cluster randomised trial. Lancet 2022;399(10339):1964 − 75. https://doi.org/10.1016/S0140-6736(22)00325-7.
[10] Schwalm JD, McCready T, Lopez-Jaramillo P, Yusoff K, Attaran A, Lamelas P, et al. A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial. Lancet 2019;394(10205):1231 − 42. https://doi.org/10.1016/S0140-6736(19)31949-X.
[11] He J, Ouyang NX, Guo XF, Sun GZ, Li Z, Mu JJ, et al. Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial. Lancet 2023;401(10380):928 − 38. https://doi.org/10.1016/S0140-6736(22)02603-4.
[12] Zhang XC, Zhang PH, Shen DY, Li Y, He FJ, Ma JX, et al. Effect of home cook interventions for salt reduction in China: cluster randomised controlled trial. BMJ 2023;382:e074258. https://doi.org/10.1136/bmj-2022-074258.
[13] Moran AE, Gupta R, Global Hearts Initiative Collaborators. Implementation of global hearts hypertension control programs in 32 low- and middle-income countries: JACC international. J Am Coll Cardiol 2023;82(19):1868 − 84. https://doi.org/10.1016/j.jacc.2023.08.043.
[14] World Health Organization. HEARTS: technical package for cardiovascular disease management in primary health care: risk-based CVD management. Geneva: World Health Organization. 2020.